Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
223
NCT02955420
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 31, 2016
Completion: May 31, 2018
NCT04192214
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
Phase: Phase 2
Start: Mar 29, 2019
Completion: Dec 6, 2022
NCT05911009
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
Start: Jun 16, 2023
Completion: Sep 4, 2024